What does Windlas Biotech do?

No Company Information Available

When is the next results date for Windlas Biotech?

No Upcoming Board Meetings

Has Windlas Biotech declared dividend?

Windlas Biotech Ltd has declared an 80% dividend, amounting to ₹4 per share, with an ex-date of September 5, 2023. Despite this, the dividend yield is 0%, and total returns have varied significantly over different periods, showing strong performance over 2 and 3 years.

Windlas Biotech Ltd has declared an 80% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 80%<BR>- Amount per share: 4<BR>- Ex-date: 05 Sep 23<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 6 months, Windlas Biotech experienced a price return of -19.79%, with no dividend return, resulting in a total return of -19.79%.<BR><BR>Over the past year, the price return was 37.84%, and there was no dividend return, leading to a total return of 37.84%.<BR><BR>In the 2-year period, the price return was 229.02%, with a dividend return of 1.30%, culminating in a total return of 230.32%.<BR><BR>For the 3-year period, the price return stood at 300.9%, with a dividend return of 3.51%, resulting in a total return of 304.41%.<BR><BR>In the 4-year period, there was no price return and no dividend return, resulting in a total return of 0.0%.<BR><BR>Over the last 5 years, there was also no price return and no dividend return, leading to a total return of 0.0%.<BR><BR>Overall, Windlas Biotech has declared a significant dividend, but the dividend yield remains at 0%. The total returns show a strong performance over longer periods, particularly in the 2 and 3-year spans, despite recent fluctuations in the shorter term.

Who are the peers of the Windlas Biotech?

Windlas Biotech's peers include Panacea Biotec, Solara Active, SMS Pharma, and others. In terms of management risk, growth, and capital structure, Windlas Biotech shows average performance, with a 1-year return of 31.46%, lower than Panacea Biotec's 215.30% but higher than Anuh Pharma's -9.06%.

Peers: Windlas Biotech's peers include Panacea Biotec, Solara Active, SMS Pharma., Amrutanjan Healt, Syncom Formul., Bajaj Healthcare, Jagsonpal Pharma, Bliss GVS Pharma, Anuh Pharma, and Beta Drugs Ltd.<BR><BR>Quality Snapshot: Excellent management risk is observed at Amrutanjan Healt, Bajaj Healthcare, and Jagsonpal Pharma, while Average management risk is found at SMS Pharma., Windlas Biotech, Syncom Formul., Bliss GVS Pharma, Anuh Pharma, and Beta Drugs Ltd, and the rest. Below Average management risk is present at Panacea Biotec and Solara Active. In terms of Growth, Good growth is seen at Jagsonpal Pharma and Beta Drugs Ltd, Average growth is noted at Anuh Pharma, while Below Average growth is observed at Panacea Biotec, Solara Active, SMS Pharma., Windlas Biotech, Syncom Formul., Amrutanjan Healt, Bajaj Healthcare, and Bliss GVS Pharma, and the rest. Excellent capital structure is noted at Amrutanjan Healt, Windlas Biotech, Syncom Formul., Jagsonpal Pharma, Bliss GVS Pharma, Anuh Pharma, and Beta Drugs Ltd, while Average capital structure is found at SMS Pharma. and Bajaj Healthcare, and Below Average capital structure is seen at Panacea Biotec and Solara Active.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Panacea Biotec at 215.30%, while the peer with the lowest is Anuh Pharma at -9.06%. Windlas Biotech's 1-year return of 31.46% is higher than Anuh Pharma's but significantly lower than Panacea Biotec's. Additionally, the six-month return is negative for Amrutanjan Healt, Windlas Biotech, Bajaj Healthcare, and Anuh Pharma.

How big is Windlas Biotech?

As of 24th July, Windlas Biotech Ltd has a market capitalization of 1,963.00 Cr, with recent net sales of 759.88 Cr and a net profit of 61.00 Cr. The company has shareholder's funds of 505.77 Cr and total assets of 760.17 Cr as of March 2025.

As of 24th July, Windlas Biotech Ltd has a market capitalization of 1,963.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, Windlas Biotech reported Net Sales of 759.88 Cr and a Net Profit of 61.00 Cr.<BR><BR>For the latest annual period ending in March 2025, the company has Shareholder's Funds amounting to 505.77 Cr and Total Assets of 760.17 Cr.

How has been the historical performance of Windlas Biotech?

Windlas Biotech has shown consistent growth from March 2020 to March 2025, with net sales increasing from 328.85 Cr to 759.88 Cr and profit after tax rising from 16.21 Cr to 60.99 Cr, reflecting strong profitability and asset expansion. Total assets grew from 337.82 Cr to 760.17 Cr, indicating robust financial performance.

Answer:<BR>The historical performance of Windlas Biotech shows a consistent growth trajectory in net sales and profits over the years, culminating in the latest figures for March 2025.<BR><BR>Breakdown:<BR>Windlas Biotech has demonstrated significant growth in net sales, increasing from 328.85 Cr in March 2020 to 759.88 Cr in March 2025. This upward trend is mirrored in total operating income, which also rose from 328.85 Cr to 759.88 Cr during the same period. The company's operating profit (PBDIT) has similarly improved, reaching 112.13 Cr in March 2025, up from 43.95 Cr in March 2020. Profit before tax has shown a steady increase, climbing from 32.14 Cr in March 2020 to 79.76 Cr in March 2025, while profit after tax reached 60.99 Cr in March 2025, compared to 16.21 Cr in March 2020. The company's total assets have expanded from 337.82 Cr in March 2020 to 760.17 Cr in March 2025, reflecting a robust growth in both current and non-current assets. Total liabilities have also increased, from 296.12 Cr in March 2020 to 760.17 Cr in March 2025, primarily driven by an increase in current liabilities. Cash flow from operating activities has fluctuated, with a notable cash flow of 68.00 Cr in March 2025, although the net cash outflow was recorded at -4.00 Cr for the same period. Overall, Windlas Biotech's financial performance indicates a strong growth trajectory with improving profitability and asset base over the years.

Are Windlas Biotech latest results good or bad?

Windlas Biotech's latest results show strong revenue growth of 18.93% year-on-year, but profitability is under pressure, with a decline in PAT margin to 8.00% due to rising costs. Overall, while revenue figures are encouraging, the challenges in profitability raise concerns about sustainability.

Windlas Biotech's latest results present a mixed picture. On one hand, the company achieved robust revenue growth, with Q2 FY26 revenues reaching ₹222.40 crores, marking an 18.93% increase year-on-year and a 5.86% increase sequentially. This reflects strong demand for its services and consistent revenue momentum over the past seven quarters.<BR><BR>However, profitability has not kept pace with this revenue growth. The operating margin improved slightly to 12.84%, but the PAT margin compressed to 8.00%, down from 8.41% in the previous quarter. This indicates challenges in operational efficiency and cost management, as rising employee costs and depreciation charges have impacted profitability.<BR><BR>While net profit did see a year-on-year increase of 13.67%, the sequential growth was only 0.79%, suggesting that the company is struggling to convert its revenue gains into proportionate profit increases. The rising costs, particularly in employee expenses, have outpaced revenue growth, raising concerns about the sustainability of profit margins.<BR><BR>In summary, while Windlas Biotech shows strong revenue growth, the accompanying margin compression and operational challenges suggest that the latest results are not entirely positive. Investors may need to weigh the encouraging revenue figures against the issues affecting profitability.

Should I buy, sell or hold Windlas Biotech?

Is Windlas Biotech technically bullish or bearish?

As of November 12, 2025, Windlas Biotech's technical trend has shifted to bearish, indicated by negative signals from MACD, RSI, Bollinger Bands, moving averages, KST, and OBV, along with significant underperformance compared to the Sensex.

As of 12 November 2025, the technical trend for Windlas Biotech has changed from mildly bearish to bearish. The current stance is bearish with a strong indication of weakness. Key indicators driving this assessment include a bearish MACD on the weekly chart, a bearish RSI on the monthly chart, and bearish signals from Bollinger Bands and moving averages across daily and weekly time frames. Additionally, the KST and OBV indicators are also bearish on the weekly chart, reinforcing the overall bearish sentiment. The stock has underperformed significantly compared to the Sensex over various periods, further supporting the bearish outlook.

Which are the latest news on Windlas Biotech?

Why is Windlas Biotech falling/rising?

As of 03-Dec, Windlas Biotech Ltd's stock price is rising to 792.00, driven by strong financial results, increased investor participation, and fair valuation metrics. Despite a decline over the past year, the company's improved profits and low debt-to-equity ratio suggest potential for recovery.

As of 03-Dec, Windlas Biotech Ltd's stock price is rising, currently at 792.00, reflecting an increase of 10.6 (1.36%). This upward movement can be attributed to several factors. Firstly, the stock has outperformed its sector by 1.37% today, indicating positive market sentiment. Additionally, there has been a notable increase in investor participation, with delivery volume rising by 105.64% against the 5-day average, suggesting heightened interest from investors.<BR><BR>Moreover, the company reported strong financial results for the quarter ending September 25, achieving the highest net sales of Rs 222.40 crore and a significant operating profit margin of 12.84%. These results contribute to a perception of fair valuation, as the stock is trading at a Price to Book Value of 3.1, which is in line with historical averages compared to its peers.<BR><BR>Despite the stock's poor performance over the past year, with a decline of 28.07%, the company's profits have increased by 10%, indicating potential for recovery. The low debt-to-equity ratio and the strong operating profit growth over the last five years also support a more favorable outlook. Overall, the combination of positive financial results, increased trading activity, and fair valuation appears to be driving the stock's rise.

Is Windlas Biotech overvalued or undervalued?

As of December 3, 2025, Windlas Biotech is fairly valued with a PE ratio of 24.80 and has underperformed with a year-to-date stock return of -23.36%, indicating potential challenges in regaining investor confidence despite not being overvalued compared to peers.

As of 3 December 2025, Windlas Biotech's valuation grade has moved from attractive to fair, indicating a shift in its perceived value. The company is currently fairly valued, with a PE ratio of 24.80, an EV to EBITDA of 13.68, and a ROCE of 24.60%. In comparison to its peers, Sun Pharma has a significantly higher PE ratio of 37.51, while Cipla is more attractive with a PE of 22.39.<BR><BR>Despite its fair valuation, Windlas Biotech has underperformed recently, with a year-to-date stock return of -23.36% compared to a Sensex return of 8.92%. This performance, along with the current ratios, suggests that while the company is not overvalued, it may face challenges in regaining investor confidence in the near term.